TCE2 Stock Overview
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Celldex Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$34.00 |
| 52 Week High | US$47.80 |
| 52 Week Low | US$21.20 |
| Beta | 1.56 |
| 1 Month Change | -10.53% |
| 3 Month Change | 0% |
| 1 Year Change | 17.24% |
| 3 Year Change | 26.96% |
| 5 Year Change | 944.23% |
| Change since IPO | -38.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| TCE2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.6% | -0.2% | 0.5% |
| 1Y | 17.2% | -22.8% | 1.3% |
Return vs Industry: TCE2 exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: TCE2 exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| TCE2 volatility | |
|---|---|
| TCE2 Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TCE2's share price has been volatile over the past 3 months.
Volatility Over Time: TCE2's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 160 | Anthony Marucci | www.celldex.com |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity.
Celldex Therapeutics, Inc. Fundamentals Summary
| TCE2 fundamental statistics | |
|---|---|
| Market cap | €2.22b |
| Earnings (TTM) | -€131.84m |
| Revenue (TTM) | €6.42m |
339.4x
P/S Ratio-16.5x
P/E RatioIs TCE2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCE2 income statement (TTM) | |
|---|---|
| Revenue | US$6.88m |
| Cost of Revenue | US$118.01m |
| Gross Profit | -US$111.13m |
| Other Expenses | US$30.30m |
| Earnings | -US$141.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.20 |
| Gross Margin | -1,614.53% |
| Net Profit Margin | -2,054.76% |
| Debt/Equity Ratio | 0% |
How did TCE2 perform over the long term?
See historical performance and comparison